Capricor projects FDA priority review decision for deramiocel by August 2025
FDA accepts Capricor's Biologics License Application for priority review, advancing deramiocel for DMD cardiomyopathy.
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
Pharmaceutical Technology on MSN18h
USPTO allows patents for Remedy’s large hemispheric infarction drug
The US Patent and Trademark Office (USPTO) has allowed two new patents for Remedy Pharmaceuticals’ Cirara to treat large ...
SaltWire15h
Charlottetown Guardian | News, Headlines and Stories | PNI Atlantic News
The Charlottetown Islanders had extra motivation on March 16, and it was all because of six young people. SUMMERSIDE, P.E.I. — It was a big Day 2 of competition at the 2025 Canadian mixed doubles ...